Ureteral Stent and Percutaneous Nephrostomy in Managing Malignant Ureteric Obstruction of Gastrointestinal Origin: A 10 Years’ Experience

IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY

Gastrointestinal disorders (Basel, Switzerland) Pub Date : 2020-12-08 DOI:10.3390/gidisord2040041

E. De Lorenzis, E. Lievore, M. Turetti, A. Gallioli, B. Galassi, L. Boeri, E. Montanari

{"title":"Ureteral Stent and Percutaneous Nephrostomy in Managing Malignant Ureteric Obstruction of Gastrointestinal Origin: A 10 Years’ Experience","authors":"E. De Lorenzis, E. Lievore, M. Turetti, A. Gallioli, B. Galassi, L. Boeri, E. Montanari","doi":"10.3390/gidisord2040041","DOIUrl":null,"url":null,"abstract":"Background: Malignant ureteral obstruction (MUO) is variable in presentation and there is no consensus on its management, especially when caused by gastrointestinal (GI) malignancies. Our aim was to describe our experience with this oncological complication. Methods: We retrospectively analyzed the outcomes of ureteral stent and nephrostomy tube (NT) positioning for GI-related MUO from 2010 to 2020. We performed descriptive analysis, survival analysis, and uni- and multi-variate analysis. Results: We included 51 patients. NT was mainly used when bladder involvement occurred and when MUO revealed an ex novo cancer diagnosis. Survival was poorer in patients with new diagnoses and in those receiving no treatment after decompression. Moreover, MUO caused by upper-GI tumors was related to shorter overall survival. Conclusions: GI tumors causing MUO should be considered of poor prognosis. Treatment decisions should be weighted accurately by both specialists and the patient.","PeriodicalId":73131,"journal":{"name":"Gastrointestinal disorders (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2020-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3390/gidisord2040041","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastrointestinal disorders (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/gidisord2040041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 7

Abstract

Background: Malignant ureteral obstruction (MUO) is variable in presentation and there is no consensus on its management, especially when caused by gastrointestinal (GI) malignancies. Our aim was to describe our experience with this oncological complication. Methods: We retrospectively analyzed the outcomes of ureteral stent and nephrostomy tube (NT) positioning for GI-related MUO from 2010 to 2020. We performed descriptive analysis, survival analysis, and uni- and multi-variate analysis. Results: We included 51 patients. NT was mainly used when bladder involvement occurred and when MUO revealed an ex novo cancer diagnosis. Survival was poorer in patients with new diagnoses and in those receiving no treatment after decompression. Moreover, MUO caused by upper-GI tumors was related to shorter overall survival. Conclusions: GI tumors causing MUO should be considered of poor prognosis. Treatment decisions should be weighted accurately by both specialists and the patient.

查看原文本刊更多论文

输尿管支架和经皮肾造口术治疗胃肠道源性恶性输尿管梗阻的10年经验

背景：恶性输尿管梗阻（MUO）在表现上是可变的，对其治疗没有共识，尤其是当由胃肠道恶性肿瘤引起时。我们的目的是描述我们对这种肿瘤并发症的经历。方法：我们回顾性分析了2010年至2020年输尿管支架和肾造瘘管（NT）定位治疗胃肠道相关MUO的结果。我们进行了描述性分析、生存分析以及单变量和多变量分析。结果：我们纳入了51例患者。NT主要用于发生膀胱受累和MUO显示新诊断为癌症时。新诊断的患者和减压后未接受治疗的患者的生存率较差。此外，上消化道肿瘤引起的MUO与较短的总生存期有关。结论：引起MUO的胃肠道肿瘤应考虑预后不良。治疗决策应由专家和患者准确权衡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gastrointestinal disorders (Basel, Switzerland)

CiteScore

1.50

自引率

0.00%

发文量

审稿时长

10 weeks